Intracerebral hemorrhage

Bayer Launches Calantic™ Digital Solutions to help Address Radiology Industry Challenges

Retrieved on: 
星期二, 六月 28, 2022
Health, Technology, Other Technology, Health Technology, Radiology, Artificial Intelligence, Department, Diagnosis, Review, Health, Patient, Ageing, Einstein Healthcare Network, Howard Johnson Co. v. Detroit Local Joint Executive Board, Conditional sentence, Research, Time, Chair, University of Texas Health Science Center Department of Radiology, Association of American Medical Colleges, Workload, Growth, Ecosystem, Complex, Agent handling, Association, Intracerebral hemorrhage, Trust, Triage, CT, Prevalence, Digital, Radiology, Automation, Magnetic resonance imaging, CAGR, Workflow, Degenerative disease, Veni, vidi, vici, Digital Solutions, Software, Cardiovascular disease, Risk, PMID, Solution, GBD, AI, Pathology, Physician, Macdonald, Mortality, MRI, Group, Cancer, Informatics, Medical imaging, Medical device, Pharmaceutical industry, Incidence, Bayer

Bayer today unveiled Calantic Digital Solutions, a new cloud-hosted platform delivering access to digital applications, including AI-enabled programs, for medical imaging.

Key Points: 
  • Bayer today unveiled Calantic Digital Solutions, a new cloud-hosted platform delivering access to digital applications, including AI-enabled programs, for medical imaging.
  • It is crucial to drive innovation in this area and broaden access to digital tools that can help address the rising demand for solutions which improve the speed and accuracy of diagnoses.
  • Built on our leading industry knowledge and deep medical understanding across a multitude of diagnostic and therapeutic areas, Calantic Digital Solutions underlines our commitment to continue accelerating innovation for the benefit of patients and their physicians, says Gerd Krger, Head of Radiology, Bayer Pharmaceuticals.
  • Calantic Digital Solutions is a suite of digital radiology AI-enabled applications which assist radiologists and their teams at critical steps within a patients treatment journey.

NICO Secures New Patent Approvals Supporting Neurosurgical Brain Access Solutions

Retrieved on: 
星期五, 五月 13, 2022
ENRICH, Neoplasm, Pearson, Patient, Human skull symbolism, Stroke, NICO, Neurosurgery, Patent, Brain, Automation, Therapy, Intracerebral hemorrhage, Collection, CEO, Medical imaging

Two new patents issued to NICO for its surgical access system, the system's assembly and method for use in brain surgery

Key Points: 
  • Two new patents issued to NICO for its surgical access system, the system's assembly and method for use in brain surgery
    "Protecting our intellectual property has always been a top priority for NICO," said Jim Pearson, president and CEO of NICO Corporation.
  • "Our technologies comprise an integrated systems approach to brain surgery that is creating new realities for neurosurgeons.
  • Pearson added that these two new patent approvals related to safe access to all regions of the brain are key to protecting the company's unique and revolutionary intellectual property.
  • NICO technologies have been featured in more than 170 peer-reviewed published papers with over 550 unique authors from major academic centers.

New Technology Enables Option for Neurosurgeons to Avoid Pinning Patients' Heads for Brain Surgery

Retrieved on: 
星期二, 三月 1, 2022
Skull, Stroke, Neurosurgery, Blood pressure, Patient, Surgeon, Spectrum Health, OR, Conference, Patent, EM, NICO, Intracerebral hemorrhage, MIPS, Human skull symbolism, Technology, MD, ICH, Brain, Therapy, Medical imaging, Medical device

This means appropriate patients will no longer have to be pinned in a rigid headframe during the navigation process providing a more compassionate minimally invasive surgery option.

Key Points: 
  • This means appropriate patients will no longer have to be pinned in a rigid headframe during the navigation process providing a more compassionate minimally invasive surgery option.
  • Simple, easy OR set-up with frameless stereotaxy & BrainPath is great option for patients when pinning is not indicated.
  • The BrainPathNavigation Probe Adapter for MedtronicStealthStationEM is used with specific navigation pointers during MIPS procedures using BrainPath.
  • EM navigation helps avoid these spikes often associated with pinning patients in a head-frame."

Insights on the Brain Hemorrhage Global Market to 2028 - by Drug Type, Distribution Channel and Region - ResearchAndMarkets.com

Retrieved on: 
星期四, 一月 13, 2022
Health, Biotechnology, Region, Hypocholesterolemia, CAGR, Research, Membrane, Stroke, Center, Korea Disease Control and Prevention Agency, Bleeding, Incidence, Skull, US, Adoption, Death, Growth, Brain damage, Pharmacy, Market share, Swelling, Hypertension, Tissue, Industry, Smoking, Marketing, Therapy, Cerebral edema, Hematoma, Blood, Intracranial hemorrhage, Brain, Intracerebral hemorrhage, Head injury, Risk, Medical imaging, Renewable energy

The "Brain Hemorrhage Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Brain Hemorrhage Market, by Drug Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • Brain hemorrhage is a medical emergency condition wherein blood vessel ruptures and causes bleeding inside the brain.
  • This bleeding can also occur between the brain and the membranes covering the brain, between the skull and the covering of the brain or between the membrane layers covering the brain.
  • Some of the risk factors associated with occurrence of brain hemorrhage include brain trauma, brain tumor, weak blood vessels, liver drug, hypertension, excessive smoking, hypocholesterolemia, excessive alcohol consumption drugs, and online Pharmacies.

Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia

Retrieved on: 
星期四, 十一月 11, 2021
Immunoglobulin therapy, Quality of life, Safety, Drug development, Myositis, Immunoglobulin G, Chronic inflammatory demyelinating polyneuropathy, Private Securities Litigation Reform Act, Degenerative disease, Health, Splenectomy, SAN, U.S. Securities and Exchange Commission, Neuromuscular Disorders, Pemphigus foliaceus, Infection, NASDAQ, Disease, Immune system, Myasthenia gravis, Coronavirus, Risk, MG, COVID-19, SC, Intracerebral hemorrhage, Forward-looking statement, Neonatal Fc receptor, PV, Rituximab, GLOBE, PF, Antibody, Pemphigus vulgaris, Autoantibody, Bruise, Patient, Bleeding, Prevalence, ITP, CIDP, Adult, Pharmaceutical industry, Vaccine

The company announced today that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China (mainland China, Hong Kong, Macau, and Taiwan) as part of the global registrational ADVANCE-SC Phase 3 study.

Key Points: 
  • The company announced today that the first patient with primary immune thrombocytopenia (ITP) was treated with efgartigimod in Greater China (mainland China, Hong Kong, Macau, and Taiwan) as part of the global registrational ADVANCE-SC Phase 3 study.
  • Also, efgartigimod appears to be well tolerated, potentially because of its unique structure and ability to bind to the FcRn receptor.
  • The prevalence of primary ITP in Greater China is estimated at 120,000 patients.
  • Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.

Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21

Retrieved on: 
星期二, 十月 5, 2021
Securities Act of 1933, VIVA, Alife, Risk, Annual report, Security (finance), Drug Quality and Security Act, Health, PE, Intention, U.S. Securities and Exchange Commission, Blood vessel, Patient, BSX, Physician, Twitter, Life, ICH, EKOS, Science, Intracerebral hemorrhage, Boston Scientific, Technology, Bleeding, Forward-looking statement, Safety, Securities Exchange Act of 1934, Intellectual property, NYSE, Time, Inova Alexandria Hospital, Boston, Medical imaging, Pharmaceutical industry, Hospital

LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ --Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.

Key Points: 
  • LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ --Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic Endovascular System (EKOS system) during a late-breaking clinical trial presentation at the Vascular InterVentional Advances (VIVA) meeting in Las Vegas.
  • The international registry of 489 patients across 83 centers included data from patients treated with the EKOS system who were provided a lower drug dose and shorter infusion duration of a thrombolytic agent than administered in previous studies, reflecting contemporary clinical practice.
  • These forward-looking statements include, among other things, statements regarding our business plans, clinical trials, product launches and product performance and impact.
  • All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.

Keches Law Group wins $7 Million Dollar Verdict in Holyoke Wrongful Death Case

Retrieved on: 
星期一, 四月 26, 2021
Neurotrauma, Neurological disorders, Skull fracture, Law, Intracerebral hemorrhage, Baystate Health, Articles, Law firm, Courtroom

The family was represented by attorneys Nicholas Rowley and Benjamin Novotny of Trial Lawyers for Justice and Charlotte Glinka and Karen Zahka of Keches Law Group, P.C.

Key Points: 
  • The family was represented by attorneys Nicholas Rowley and Benjamin Novotny of Trial Lawyers for Justice and Charlotte Glinka and Karen Zahka of Keches Law Group, P.C.
  • She was taken by ambulance to Baystate Medical Center in Springfield where a CT scan revealed a skull fracture and a brain hemorrhage.
  • For the last three years, the defendant refused to take responsibility for their mother\'s death.
  • said Attorney Nicholas Rowley.\nThe docket number for the case is 1879CV00247-B.\nKeches Law Group has become one of the largest and most well-respected personal injury law firms in New England.

How Common Is Stroke in People Critically Ill with COVID-19?

Retrieved on: 
星期五, 四月 16, 2021
Stroke, Cerebrovascular diseases, Intracerebral hemorrhage, Health, COVID-19, Articles, Medical specialties

The preliminary study will be presented at the American Academy of Neurology\'s 73rd Annual Meeting being held virtually April 17 to 22, 2021.

Key Points: 
  • The preliminary study will be presented at the American Academy of Neurology\'s 73rd Annual Meeting being held virtually April 17 to 22, 2021.
  • "However, among the sickest of patients, those admitted to an ICU, our research found that stroke was not a common complication and that a stroke from a blood clot did not increase the risk of death.
  • However, people who had a stroke from a clot had no increased risk of death.\nOf the people with bleeding stroke, 72% died, but of those, only 15% died of stroke.
  • "Still, COVID-19 is a new disease and mutations have resulted in new variants, so it\'s important to continue to study stroke in people with the disease.

Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy

Retrieved on: 
星期一, 一月 11, 2021
Neurotrauma, Medical specialties, Cerebrovascular diseases, Stroke, Branches of biology, Medicine, Intracerebral hemorrhage, Medical diagnosis, Bleeding

Amydis has reached agreement with the FDA on both nonclinical and clinical plans.

Key Points: 
  • Amydis has reached agreement with the FDA on both nonclinical and clinical plans.
  • CAA is a major cause of spontaneous intracerebral hemorrhage in people older than 55 and an important contributor to age-related cognitive decline.
  • I am keenly aware of the challenges CAA patients face in the diagnosis and treatment of disease.
  • I believe that diagnosis of CAA through the eye would be a tremendous step forward for the field.

Survivor of Life-Threatening Brain Surgery Shares His Story of Hope, Resilience and Recovery in Inspirational New Memoir

Retrieved on: 
星期一, 十月 19, 2020
Medical specialties, Clinical medicine, Neurotrauma, Medicine, Intensive care medicine, Brain damage, Induced coma, Traumatic brain injury, Coma, Intracerebral hemorrhage, Head injury, Cerebral contusion

As the tumor grew, he had no choice but to have brain surgery bringing tremendous fear to Plaskas and his family.

Key Points: 
  • As the tumor grew, he had no choice but to have brain surgery bringing tremendous fear to Plaskas and his family.
  • During the operation Plaskas suffered a brain hemorrhage, losing a massive amount of blood and was placed in a medically induced coma.
  • Plaskas details the emotional and physical toll his life-threatening brain surgery brought him and how he was able to overcome obstacles the brain injury had caused.
  • I want people to know a severe brain injury survivor can accomplish many recovery goals if they have confidence, determination and hard work, said Plaskas.